Call it Smart Ultrasound®
Software with vision. It has the power to meaningfully elevate the quality of medical care and support accurate decision-making by ‘seeing’ what humans can’t.
In the USA alone…
More than 350 breast cancer cases evade early detection because of misdiagnosis. Many of the errors can be avoided. Physicians interpret the same cases differently, up to one in three cases. Up to 80% of biopsies typically come back benign. In addition, sensitivity benchmarks are 85% implying that 15% of presented cancers to the screening and diagnostic pathway are missed. Machine learning and Koios DS™ Breast decision support are here to help.
Quick & Accurate Diagnosis
Our proprietary algorithms are trained to deliver instantaneous results based on hundreds of thousands of similar cases where the correct diagnosis is already known.
Rapid Deployment
Simply download the Koios DS software and configure your settings to your PACS.
No coding required. We offer seamless workflow integration, by design.
The Koios owl icon appears within your viewer. Drag your mouse over the image you want to review. In 2 seconds or less, the results can be exported directly into your image (or ultrasound) reporting solution.
No patient data ever leaves your premises. Yes, it’s that easy.
Less Clerical, More Clinical®
Koios DS enables an automated workflow that was previously unimaginable, giving physicians back precious minutes to concentrate on what matters most. Our engineers designed algorithms to help in the fight against cancer, and software to battle physician fatigue, stress and burnout. Koios DS computer vision classifies lesions and eliminates manual data entry and the errors that go along with it.
Results that Matter
Machines perform analysis that improves the delivery of quality care, tracking, and reporting.
We work backwards from what matters most to patients and physicians.
Research Proven
A study published in the Journal of Digital Imaging demonstrates that Koios DS improved accuracy in breast cancer diagnosis for radiologists across all levels of experience. Sensitivity increased from a range of 92–97% to a range of 97–98%, and specificity increased from a range of 38–46% to a range of 45–52%. At the same time, benign biopsy rates were reduced 25–55% without a reduction in sensitivity.
A second study, published in 2017, by Dr. Susan Love and Dr. Wendie Berg published in Cancer Research found a cancer identification rate of 100% with a 69% reduction in benign biopsies.
Simplicity is key.
1. Select a region of interest
2. Analyze
3. Save
Ready to get started?
Koios DS is available through all major PACS and on the GE Healthcare LOGIQ™ E10 scanner. Ask to learn more about how the Koios Owl can help you and your patients, or contact us directly to schedule a personal interactive demo and get a quote.
View Online Demo